سعر بالوتيك 0.25 مجم/5مل امبول 2025

Palonosetron 0.25 mg/5 ml solution for intravenous injection (ampoule), a 5-HT3 receptor antagonist antiemetic, marketed in Egypt.

• Prevention of acute and delayed nausea and vomiting with moderately emetogenic chemotherapy, and acute nausea and vomiting with highly emetogenic chemotherapyPopulation: AdultsDailyMed (NLM)
• Prevention of postoperative nausea and vomiting for up to 24 hoursPopulation: AdultsDailyMed (NLM)
• Prevention of acute chemotherapy-induced nausea and vomiting, including highly emetogenic chemotherapyPopulation: Pediatric patients 1 month to <17 yearsDailyMed (NLM)

• Most common in chemotherapy-induced nausea and vomiting in adults (>=5%): headache and constipation; in PONV (>=2%): QT prolongation, bradycardia, headache and constipation.International label, same formulation · DailyMed (NLM)

• Known hypersensitivity to palonosetron or any of its components.International label, same formulation · DailyMed (NLM)

• Hypersensitivity reactions including anaphylaxis, with or without known hypersensitivity to other 5-HT3 antagonists; discontinue and treat.International label, same formulation · DailyMed (NLM)
• Serotonin syndrome has been reported with 5-HT3 antagonists, mostly with concomitant serotonergic drugs; monitor and discontinue if symptoms occur.International label, same formulation · DailyMed (NLM)

• Serotonergic drugs (SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, IV methylene blue)Increased risk of serotonin syndrome; monitor.DailyMed (NLM)

• Palonosetron: Blocks serotonin 5-HT3 receptors on vagal afferents and in the chemoreceptor trigger zone.